R&D channel feed

Guest col­umn: The re­al cost of drug de­vel­op­ment

7 years ago
Biotech Voices
Pharma

Mer­ck KGaA posts mixed da­ta from their big PhI­Ib MS study on evo­bru­ti­nib — spurring plen­ty of ques­tions

7 years ago

Bris­tol-My­ers con­cedes a PhI­II lung can­cer flop for Op­di­vo as com­pe­ti­tion heats up in SCLC

7 years ago

Im­mune De­sign buries its PhI­II work on can­cer, and in­vestors hit the pan­ic but­ton

7 years ago

Drop in clin­i­cal tri­al num­bers un­der­scores drug­mak­er­s' fears over Brex­it that trace back over a year

7 years ago
Pharma

No­var­tis builds its case for a new sick­le cell drug, eye­ing a de­layed FDA fil­ing in ‘19

7 years ago
Pharma

Ex­clu­sive: At Hal Bar­ron’s R&D group at GSK, con­sen­sus is out, lead­ers are in and watch out for an ‘in­tense dri­ve’ to spur the late-stage pipeline

7 years ago
People

Check­point ther­a­pies be­fore surgery? MD An­der­son team re­ports en­cour­ag­ing ef­fi­ca­cy but wor­ries about tox­i­c­i­ty

7 years ago

One of Af­fimed’s new glass slip­pers cracks as a dead­ly in­ci­dent forces halt to PhI can­cer tri­als

7 years ago

Men­lo’s so­lo pipeline drug suf­fers an­oth­er ug­ly tri­al fail­ure, done in by an out­per­form­ing place­bo

7 years ago

Can­cer drug ri­vals at Loxo and Blue­print go toe-to-toe once again, and one an­a­lyst scores a (pos­si­ble) win on points

7 years ago

Xen­cor’s lead drug fails a PhII test for lu­pus, shares slide

7 years ago

Eli Lil­ly ush­ers up-and-com­ing GIP/GLP-1 drug in­to PhI­II as No­vo Nordisk ri­val wows with im­pres­sive re­sults

7 years ago

Roche just her­ald­ed a great set of place­bo com­par­isons for their new flu drug — too bad it flopped against gener­ic Tam­i­flu

7 years ago

Genen­tech takes aim at Bio­gen and No­var­tis, high­light­ing an ear­ly look at pos­i­tive re­sults for their oral SMA drug from PTC

7 years ago

UK alarm bells are ring­ing as a biotech cuts a few tri­al sites, fret­ting over Brex­it’s im­pact on drug de­vel­op­ment

7 years ago
Pharma

Eli Lil­ly steers URLi to­ward the FDA af­ter scor­ing pos­i­tive re­sults in a pair of PhI­II di­a­betes tri­als

7 years ago
Pharma

Are drug R&D costs ex­ag­ger­at­ed for ef­fect? Re­searchers peg the me­di­an price of piv­otal suc­cess at an eco­nom­i­cal $19M

7 years ago

Giv­ing it a GO: Gi­ant Roche se­lects a tiny play­er at Lab­Cen­tral for its next can­cer R&D part­ner

7 years ago
Pharma

J&J shrugs off deals with Aduro that were worth up to $1.2B. Set­back forces shift to No­var­tis al­liance now

7 years ago

Mer­ck’s can­cer R&D jug­ger­naut ties up to lit­tle Drag­on­fly’s nat­ur­al born killer plat­form — with bil­lions on the line

7 years ago
Pharma

Loy­ola is work­ing on a new and im­proved CAR-T prod­uct, look­ing to over­come high-fre­quen­cy side ef­fects

7 years ago
Startups
Cell/Gene Tx

On the heels of a glob­al R&D re­or­ga­ni­za­tion, No­vo Nordisk out­lines 250 US job cuts

7 years ago

Al­ny­lam shoots for a speedy FDA OK af­ter their next shot at field­ing a pricey rare dis­ease drug hits PhI­II goal

7 years ago
First page Previous page 261262263264265266267 Next page Last page
A service from the Financial Times